`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`
`
`COALITION FOR AFFORDABLE DRUGS VIII, LLC
`Petitioner,
`
`v.
`
`THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
`Patent Owner
`
`______________
`
`Case: IPR2015-01836
`Patent No. 7,932,268
`______________
`
`DECLARATION OF NICHOLAS K. MITROKOSTAS IN SUPPORT OF
`PATENT OWNER’S MOTION FOR PRO HAC VICE ADMISSION OF
`NICHOLAS K. MITROKOSTAS UNDER 37 C.F.R. § 42.10(c)
`
`
`
`
`
`
`
`
`
`
`
`PENN EX. 2017
`CFAD V. UPENN
`IPR2015-01836
`
`
`
`I, Nicholas K. Mitrokostas, declare as follows:
`
`1.
`
`I obtained a B.A. from Harvard College in 1999, and a J.D. from
`
`Georgetown University Law Center in 2003.
`
`2.
`
`I am currently a partner in the law firm of Goodwin Procter LLP, a
`
`position which I have held since 2011. In my 12 years of law practice, I have
`
`focused primarily on representing clients in patent litigations involving the
`
`pharmaceutical and chemical arts in United States district courts and the Court of
`
`Appeals for the Federal Circuit. Through this work, I have gained extensive
`
`experience as a litigating attorney, particularly in patent cases.
`
`3.
`
`I am a member in good standing of the Bars of the Commonwealth of
`
`Massachusetts and the State of New York. I am admitted to practice before the
`
`United States District Court for the District of Massachusetts. I am also admitted
`
`to practice before the United States Court of Appeals for the Federal Circuit, and
`
`the Supreme Court of the United States.
`
`4.
`
`Concurrently with this application, I am applying to appear pro hac
`
`vice in IPR2015-01835. In the past three years, I have successfully applied to
`
`appear pro hac vice before the Office in the following proceedings: IPR2015-
`
`00643, IPR2015-00644, and IPR2015-00830 (all on behalf of Yeda Research and
`
`Development Co. Ltd.).
`
`
`
`
`1
`
`
`
`
`
`PENN EX. 2017
`CFAD V. UPENN
`IPR2015-01836
`
`
`
`5.
`
`I have over a decade of experience litigating patent cases involving
`
`the chemical and pharmaceutical arts. Below is a brief listing of some of the recent
`
`cases I have litigated in this area:
`
`
`
`a.
`
`Trial counsel in Teva Branded Pharmaceutical Products R&D
`
`Inc. et al v. Perrigo Pharmaceuticals Co. et al., Case No. 1:12-
`
`cv-01101-GMS (D. Del.)
`
`b.
`
`Trial counsel in Pfizer Inc. et al. v. IVAX Pharmaceuticals Inc.,
`
`Case No. 2:07-cv-00174-DMC-MF (D.N.J.)
`
`c.
`
`Trial counsel in In Re Bendamustine Consolidated Cases, Case
`
`No. 1:13-cv-02046-GMS (D. Del.)
`
`d.
`
`Trial and appellate counsel in Teva Pharmaceuticals USA, Inc.
`
`et al v. Mylan Pharmaceuticals Inc. et al., Case No. 1:09-cv-
`
`08824-WHP (S.D.N.Y)
`
`e.
`
`Trial and appellate counsel in Teva Pharmaceuticals USA, Inc.
`
`et al v. Mylan Pharmaceuticals Inc. et al., Case No. 1:10-cv-
`
`07246-KBF (S.D.N.Y.)
`
`6.
`
`I have substantial familiarity with the subject matter at issue in this
`
`proceeding. I have developed a strong familiarity with U.S. Patent No. 7,932,268,
`
`its prosecution history, its general subject matter, and the prior art references relied
`
`upon by Petitioner in support of its invalidity grounds in this proceeding.
`
`
`
`
`2
`
`
`
`PENN EX. 2017
`CFAD V. UPENN
`IPR2015-01836
`
`
`
`
`
`Furthermore, I have thoroughly reviewed the Petition and accompanying Exhibits
`
`submitted in this proceeding.
`
`7.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`8.
`
`I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`9.
`
`I have never been subject to any sanction or contempt citation
`
`imposed by any court or administrative body.
`
`10.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`11.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et. seq. and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a).
`
`12.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct. I further declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under section 1001 of title 18 of the United States Code, and that such willful false
`
`
`
`
`3
`
`
`
`PENN EX. 2017
`CFAD V. UPENN
`IPR2015-01836
`
`
`
`statements may jeopardize the validity of the application or any patent issued
`
`thereon.
`
`Executed on: May 5, 2016
`
`/Nicholas K. Mitrokostas/
`Nicholas K. Mitrokostas
`
`
`
`
`4
`
`
`
`
`
`
`
`PENN EX. 2017
`CFAD V. UPENN
`IPR2015-01836